Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Thorne, S. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Hwang, T. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by O’Gorman, W. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Bartlett, D. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Sei, S. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Kanji, F. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Brown, C. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Werier, J. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Cho, J. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Lee, D. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Wang, Y. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Bell, J. in: PubMed | Google Scholar

¹Department of Pediatrics and Bio-X Program, James H. Clark Center, Stanford University School of Medicine, Stanford, California, USA. ²Jennerex Biotherapeutics, San Francisco, California, USA. ³Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ⁴Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA. ⁵Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. ⁶Viral Vector Toxicology Section, LHTP, SAIC-Frederick Inc., National Cancer Institute–Frederick, Frederick, Maryland, USA. ⁷Ottawa Health Research Institute, Ottawa, Ontario, Canada. ⁸Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Ontario, Canada. ⁹Ottawa General Hospital, Ottawa, Ontario, Canada. ¹⁰Department of Radiology and ¹¹Department of Pharmacology, Medical College of Dong-A University, Busan, Republic of Korea. ¹²Barts and the London School of Medicine and Dentistry, Queen Mary’s University of London, London, United Kingdom.

Address correspondence to: David H. Kirn, Jennerex Biotherapeutics, One Market Street, San Francisco, California 94105, USA. Phone: (415) 281-8886; Fax: (415) 598-2600; E-mail: dkirn@jennerex.com.

Find articles by Kirn, D. in: PubMed | Google Scholar